Skripsi
HUBUNGAN DOSIS KELASI BESI DEFERIPRONE DENGAN PENURUNAN KADAR FERRITIN PASIEN THALASSEMIA ANAK
Thalassemia is a genetic disorder caused by defects in the production of one or more globin subunits of hemoglobin. In thalassemia major, patients are prone to hemolysis and require regular blood transfusions. Hemolysis and routine blood transfusions can lead to iron accumulation in the body, resulting in elevated ferritin levels, the main iron storage protein. High ferritin levels indicate excessive iron buildup, requiring iron chelation therapy to help remove the excess iron. One such chelation therapy is deferiprone. This study aims to determine the relationship between the deferiprone iron chelation dose and ferritin level reduction in pediatric thalassemia patients at RSUP dr. Mohammad Hoesin Palembang. This is an observational analytic study with a cross-sectional design conducted on 69 major thalassemia patients at RSUP dr. Mohammad Hoesin Palembang who met the inclusion criteria. The samples in this study received the same deferiprone dose for 3-6 months and had at least two ferritin level measurements. Chi-Square analysis was performed to examine the relationship between deferiprone dosage and serum ferritin reduction. In this study, it was found that the majority of patients received a deferiprone dosage of ≤77.95 mg/kg body weight. Only 36.2% of patients reached the target ferritin reduction, and no significant relationship was found between deferiprone dosage and the reduction of serum ferritin levels (P=0.051). No relationship was found between the deferiprone iron chelation dose and ferritin level reduction in pediatric thalassemia patients at RSUP dr. Mohammad Hoesin Palembang. Keywords: Ferritin levels, deferiprone, pediatric thalassemia.
| Inventory Code | Barcode | Call Number | Location | Status |
|---|---|---|---|---|
| 2407006855 | T161312 | T1613122024 | Central Library (REFERENCE) | Available but not for loan - Not for Loan |
No other version available